论文部分内容阅读
目的 探讨术前化疗对乳癌端粒酶活性的影响及其机制。方法 40例乳癌病人分为 :(1)化疗组 ,32例。行 1～ 3次的术前CMF(环磷酰氨、氨甲喋磷、氟脲嘧啶 )方案治疗 ;(2 )对照组 ,8例。未行术前化疗或放疗。检测两组的乳癌肿瘤组织端粒酶活性 (TA)。结果 化疗组端粒酶活性 (TA =0 .499)较对照组 (TA =1.0 18)明显降低 (P <0 .0 0 1) ;且发现 :化疗 1次、2次、3次端粒酶活性分别为 0 .812 ,0 .492和 0 .2 80 ,说明术前化疗次数越多 ,乳癌组织的端粒酶活性下降越明显。结论 乳癌术前CMF方案化疗能明显抑制端粒酶活性 ,其活性降低程度与化疗次数呈正相关。端粒酶活性可考虑作为化疗效果的观察指标和为进一步治疗决策或选择化疗提供依据。
Objective To investigate the effect of preoperative chemotherapy on telomerase activity in breast cancer and its mechanism. Methods 40 cases of breast cancer patients were divided into: (1) chemotherapy group, 32 cases. One to three times preoperative CMF (cyclophosphamide, carbamophos, fluorouracil) regimen; (2) control group, 8 cases. No preoperative chemotherapy or radiotherapy. Telomerase activity (TA) was detected in both breast cancer tumor tissues. Results The telomerase activity (TA = 0. 499) in the chemotherapy group was significantly lower than that in the control group (TA = 1.0 18) (P < 0.01), and telomerase was detected once, twice and three times in the chemotherapy group. The activities were 0.812, 0.492 and 0.280, respectively, indicating that the more preoperative chemotherapy times, the more obvious the decline of telomerase activity in breast cancer tissues. Conclusion Preoperative CMF chemotherapy can significantly inhibit telomerase activity in breast cancer, and the decrease in its activity is positively correlated with the number of chemotherapy. Telomerase activity may be considered as an indicator of the efficacy of chemotherapy and provide a basis for further treatment decisions or the choice of chemotherapy.